{‘She has no experience’: this American scientific community prepares for Dr. Høeg's role at the Food and Drug Administration.

Given that the US undertakes sweeping adjustments to its immunization guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid vaccinations during the pandemic and has concentrated on potential fatalities following Covid immunization in her recent position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Health officials planned to reveal major revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would place the US at odds with many the global community with no evidence for public health gain. The planned update has been delayed until the next year.

Instead of the top vaccines chief, Høeg is scheduled to address the audience at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the center this year.

Consolidating Power at the Agency

This interim role could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending specific childhood shot schedules in the US so as to align more in line with Denmark's approach, a nation with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no apparent experience in medication creation, regulation or administrative roles, which has been standard for past heads of the CBER. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the CDER, said Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “understand laws and regulations and the science of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who led CBER have had.”

This division has an vast workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the novel medication approvals, but the generic program clears thousands of generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and each of these need to be looked after,” Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major management component to the position, which manages more than 5,000 personnel. “It’s a massive leadership role, if you execute it properly,” the former official said.

Agency Reaction and Disputed Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this assignment indicates more teamwork among FDA leaders on vaccines, a press secretary responded that the “inquiries are based on inaccurate presumptions”.

“This background aligns with the duties of her role,” the representative explained, pointing to the time Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg inherits the agency head's recently launched priority voucher program, a contentious one-day medication authorization process that allegedly troubled her preceding directors. “By what process are these medications being selected for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the regulatory body right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, with the exception of vaccines.”

Public Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if problematic, track record, critics said. She released a research paper using unconfirmed public submissions to estimate the incidence of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the current administration included altering guidelines for novel immunizations and discontinuing “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has according to sources proposed excluding teenage boys from getting Covid vaccinations.

“She’s an complete true believer who commences with her conclusions and reverse-engineers to fit the evidence in a very disingenuous, dishonest fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of other contrarians, {like|